Early Access — free while we kick the tires
EdgarHawk

Shizuru Judith Anne

Director

Director
1 filing analyzed · 1 company · Latest 2025-09-24

Companies

Company Buys Sells Direction
Jasper Therapeutics, Inc. JSPR 1 0 Net buying

Activity

September 2025
high
Buy
41,000 shares
$99,630
Significance 7/10

Director Shizuru Judith Anne bought 41,000 shares of JSPR at $2.43; stock down -90.6% from 52-week high; 3 other insiders also buying in 14-day window

Director Shizuru Judith Anne purchased 41,000 shares at $2.43, increasing her holdings by 35.4% from 115,901 to 156,901 shares. The stock is trading at $2.33, representing a -90.6% decline from its 52-week high of $24.73 and down -59.0% over the past 90 days. Notably, 3 other insiders have also purchased within the past 14 days, forming a cluster buy pattern. The company reported a net income of -$26,723,000 over its most recent fiscal year, indicating ongoing unprofitability, and carries a market cap of $37,870,263.56. This coordinated accumulation at deeply depressed price levels by multiple insiders warrants investor attention as a potential signal of management's view on risk/reward at current valuations.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access